CytoDyn completes qualification of PRO 140 material for phase 3
CytoDyn announced that the Company's QA/QC expert, Dr. Robert Schiff, has approved for release inventory suitable to satisfy CytoDyn's current Phase 3 trial. The Company's 25-week Phase 3 trial includes 300 patients and will require approximately 15,000 vials of PRO 140. July 29, 2015